2026-01-13 - Analysis Report
**Simple Numbers:**

* Cumulative return of review stock: 26.09%
* Cumulative return of comparison stock (S&P 500, VOO): 94.34%
* Divergence: -66.40
* Relative divergence: 25.20%
* 5-day SMA: $109.64
* 20-day SMA: $105.14
* 60-day SMA: $96.84
* RSI: 76.51
* PPO: 0.11
* MRI: 0.80
* Expected Return: -26.70%

**Analysis:**

1. **Return Rate Comparison:**

The cumulative return of the review stock (MRK) is significantly lower than the comparison stock (VOO) at 26.09% vs. 94.34%. The degree of divergence is -66.40, indicating a significant difference in performance.

2. **Stock Price Fluctuations:**

The recent stock price fluctuations are:

* Close: $109.19
* Last-market: -1.21% from $110.53
* 5-day SMA: $109.64
* 20-day SMA: $105.14
* 60-day SMA: $96.84
The stock price has shown a sharp decline in the recent session.

3. **RSI, PPO, and Delta_Previous_Relative_Divergence Analysis:**

The indicators suggest a moderate risk level with a Risk Management Indicator (MRI) of 0.80. The RSI is at 76.51, indicating overbought conditions. The PPO is at 0.11, suggesting a potential sell signal. The recent relative divergence change is improving, and the 7-day Dynamic Expected Return change is also improving.

4. **Recent News and Significant Events:**

The recent news headlines suggest that the stock price may be influenced by factors such as deal buzz, vaccine risk, and cancer drug potential. The recent news headlines include:

* Merck stock slides as JPMorgan conference tests deal buzz and vaccine risk
* Merck stock rating reiterated at Buy by UBS on cancer drug potential
* Is Merck Stockâ€™s Run Legitimate?

5. **Analyst Opinions:**

The analyst consensus is:

* Key: Buy
* Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
* Opinions: 27
* Target Price (avg/high/low): 113.33 / 135.00 / 83.00

6. **Recent Earnings Analysis:**

The recent earnings analysis suggests:

| Date | EPS | Revenue |
| --- | ---:| ---:|
| 2025-11-05 | 2.32 | $17.28 B |
| 2025-08-05 | 1.76 | $15.81 B |
| 2025-05-02 | 2.01 | $15.53 B |
| 2024-11-06 | 1.25 | $16.66 B |
| 2025-11-05 | 1.25 | $16.66 B |

The EPS and revenue have shown fluctuations over the past few quarters.

7. **Comprehensive Analysis (Summary of previous items):**

The comprehensive analysis suggests that the stock price has shown a sharp decline in recent sessions. The indicators suggest a moderate risk level, and the recent news headlines suggest that the stock price may be influenced by factors such as deal buzz and vaccine risk. The analyst consensus is to buy the stock, and the target price is set at an average of $113.33.

**Risk Level:** Medium

**Potential Impact:** Potential sell signal due to overbought conditions and sharp decline in stock price.

**Recommendation:** Consider selling or holding the stock due to the current indicators and analysis.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.